Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lumos Pharma Inc (LUMO)

Lumos Pharma Inc (LUMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Lumos Pharma Completes Successful Tender Offer and Merger with Double Point Ventures Quiver Quantitative, Inc. - Thu Dec 12, 2024

Lumos Pharma completed its merger with Double Point Ventures, acquiring a majority of shares through a tender offer.Quiver AI SummaryLumos Pharma, Inc. and Double Point Ventures LLC announced the completion...

LUMO : 4.34 (unch)
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma GlobeNewswire - Thu Dec 12, 2024

LUMO : 4.34 (unch)
Lumos Pharma Presents New Data on LUM-201 from Phase 2 Trials for Pediatric Growth Hormone Deficiency at ESPE 2024 Quiver Quantitative, Inc. - Thu Nov 21, 2024

Lumos Pharma presented positive Phase 2 trial data for oral LUM-201, showing sustained growth in pediatric patients with hormone deficiency.Quiver AI SummaryLumos Pharma, Inc. has presented new analyses...

LUMO : 4.34 (unch)
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action GlobeNewswire - Thu Nov 21, 2024

LUMO : 4.34 (unch)
Lumos: Q3 Earnings Snapshot AP - Fri Nov 8, 2024

Lumos: Q3 Earnings Snapshot

LUMO : 4.34 (unch)
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) GlobeNewswire - Wed Oct 23, 2024

LUMO : 4.34 (unch)
Lumos: Q2 Earnings Snapshot AP - Thu Aug 1, 2024

Lumos: Q2 Earnings Snapshot

LUMO : 4.34 (unch)
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates Globe Newswire - Tue Aug 9, 2022

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...

LUMO : 4.34 (unch)
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022 Globe Newswire - Wed Jul 27, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 4.34 (unch)

Barchart Exclusives

Why Coca-Cola and Walmart Top This List of Steady, Low-Volatility Dividend Aristocrats Barchart - Fri Jun 5, 6:00PM CDT
Dividend Aristocrats can offer income, stability, and consistency. Here are four lower-volatility names analysts still like. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.